Search

Displaying results 5491 - 5500 of 7452 in total
  1. Drug

    Streptococcus pneumoniae type 23B capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB19349
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.

  2. Drug

    Streptococcus pneumoniae type 24F capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB19350
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.

  3. Drug

    Streptococcus pneumoniae type 31 capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB19351
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.

  4. Drug

    Streptococcus pneumoniae type 35B capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB19352
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.

  5. Drug

    Streptococcus pneumoniae type 12F capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB16716
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.

  6. Drug

    Liranaftate

    go.drugbank.com/drugs/DB19985
    Experimental

    Liranaftate is a small molecule drug. Liranaftate has a monoisotopic molecular weight of 328.12 Da.

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  7. Drug

    SARS-CoV-2 Sclamp

    go.drugbank.com/drugs/DB15849
    Investigational

    As of July 13, 2020, the candidate is being tested for safety and immunogenicity in Phase 1 clinical trials in Queensland (ACTRN12620000674932). … The University of Queensland (UQ), in partnership with The Coalition for Epidemic Preparedeness Inovations (CEPI) and CSL has developed a COVID-19 candidate, SARS-CoV-2 Sclamp.

  8. Drug

    MLN0415

    go.drugbank.com/drugs/DB05183
    Experimental

    Because inflammatory proteins play a critical role in inflammation and drive the inflammatory response to disease, controlling these proteins may prevent or slow disease progression.

  9. Drug

    Amfecloral

    go.drugbank.com/drugs/DB08924
    Experimental

    For a short period of time, it was available under the brand Acutran and indicated as an appetite suppressant, but this product no longer exists. … It acts as a prodrug which splits to form amphetamine and chloral hydrate, similarly to clobenzorex and related compounds, except that the N-substituent, in this case, yields a compound that is active

  10. Drug

    EGT-101

    go.drugbank.com/drugs/DB17645
    Experimental

    Developed by Esteve Pharmaceuticals, it is being investigated for Sanfilippo syndrome type A.[L45919]